Trial Profile
Multi-disciplinary research for predictive factors of nivolumab effect on unresectable or metastatic renal cell carcinoma.
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 05 Mar 2018
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 05 Mar 2018 New trial record